Jesse Gelsinger
Jesse Gelsinger died after receiving a genetic therapy treatment for a liver disease. Death triggered an investigation and caution around genetic therapy, ending the research for several years.
September 17, 1999: 26 years ago, a teenager who had received experimental genetic therapy died.
A Death of Jesse Gelsinger led to changes in the process of clinical trials and also to skepticism that would wage the field of genetic therapy for years.
Jesse Gelsinger was 18 years old and suffered from ornitine transcarbamilase (OTC) deficiency, a genetic disease that affects about 1 in 40,000 newborns. The condition prevents the body from producing an enzyme that usually decomposes ammonia, a natural product of metabolism. Without this enzyme, ammonia accumulates in the body and poisons the blood.
About 90 % of babies with the most severe form of OTC deficiency die. But Gelsinger – which had a lighter, “late onset” form – had reached adulthood strictly following a poor protein diet and a 50 compressed regime a day to help reduce the amount of ammonia in the blood and counteract their effects.
Gelsinger wanted to help newborns with the disease, so he signed up for a test to test the safety of a genetic therapy designed to correct the defective OTC gene.
As explained by, the treatment used a weakened form of adenoviruses, a type of constipation viruses, to deliver the corrected form of the OTC gene to Gelsinger cells.
Gelsinger went to the University of Pennsylvania, where the rehearsal took place, and received the treatment infused in the artery that feeds the liver on September 13 of 1999.
That day there was similar symptoms to the flu, as expected. But the next day it was icly, it developed a Severe inflammatory reaction and a coagulation disturbance; and the organs started to fail.
Died on September 17. The investigations revealed that the death was caused by a severe immune reaction to the virus used to manage treatment.
According to, the Food and Drug Administration (FDA) found numerous problems in Gelsinger’s inscription in the rehearsal.
First, the liver function was too compromised and ammonia levels were too high when the essay started.
Second, the team did not reveal to patients that, before the rehearsal, laboratory animals had died with higher doses of therapy. In addition, other human participants had had serious adverse effects.
As Live Science tells, James Wilsonmain investigator, had actions by Genovo, the company that developed therapy, and could profit millions If the treatment was successful.
A stop in the study of genetics
Jesse Gelsinger’s death threw a shadow over the field of genetics and, as public and private financing for this approach dried, the This type of therapy was stagnant.
Jesse Gelsinger’s death led to several changes In the way genetic therapy clinical trials are conducted, as well as the strongest requirements of informed consent.
All ongoing genetic therapy tests at the University of Pennsylvania were suspended. The FDA also required more rigorous monitoring of genetic therapy tests.
With progress in understanding the viral vectors used to manage genetic therapy, and later, with the advent of the genetic editing tool, the countryside was able to recover.
However, scientists have already used genetic therapy to treat many rare genetic diseases, including severe combined immunodeficiency and multiple forms of blindness.
